FDA Panel to Review AtriCure’s Synergy Ablation System on October 26

AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, announced that a U.S. Food and Drug Administration’s (FDA) Circulatory System Devices Panel meeting is scheduled to review AtriCure’s Premarket Approval Application (PMA) for its Synergy Ablation System on October 26, 2011. AtriCure submitted the final module of its PMA in December 2010 for an atrial fibrillation (AF) indication during open-heart concomitant procedures. About AtriCure, Inc. AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions in cardiac tissue and systems for the exclusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation products for the treatment of AF during concomitant open-heart surgical procedures and sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke. AtriCure is conducting clinical trials in support of an AF indication. However, to date, the FDA has not cleared or approved AtriCure’s products for the treatment of AF or a reduction in the risk of stroke.